Literature DB >> 33419781

Interventional Radiology for Local Immunotherapy in Oncology.

Lambros Tselikas1,2, Stephane Champiat3, Rahul A Sheth4, Steve Yevich4, Samy Ammari5, Frederic Deschamps6, Siham Farhane3, Charles Roux6, Sandrine Susini2, Severine Mouraud2, Alexandre Delpla6, Thibault Raoult7, Caroline Robert8,9, Christophe Massard3,9, Fabrice Barlesi9, Jean-Charles Soria9, Aurélien Marabelle2,3, Thierry de Baere6,9.   

Abstract

Human intratumoral immunotherapy (HIT-IT) is under rapid development, with promising preliminary results and high expectations for current phase III trials. While outcomes remain paramount for patients and the referring oncologists, the technical aspects of drug injection are critical to the interventional radiologist to ensure optimal and reproducible outcomes. The technical considerations for HIT-IT affect the safety, efficacy, and further development of this treatment option. Image-guided access to the tumor allows the therapeutic index of a treatment to be enhanced by increasing the intratumoral drug concentration while minimizing its systemic exposure and associated on-target off-tumor adverse events. Direct access to the tumor also enables the acquisition of cancer tissue for sequential sampling to better understand the pharmacodynamics of the injected immunotherapy and its efficacy through correlation of immune responses, pathologic responses, and imaging tumor response. The aim of this article is to share the technical insights of HIT-IT, with particular consideration for patient selection, lesion assessment, image guidance, and technical injection options. In addition, the organization of a standard patient workflow is discussed, so as to optimize HIT-IT outcome and the patient experience. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 33419781     DOI: 10.1158/1078-0432.CCR-19-4073

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  5 in total

1.  Intratumorally anchored cytokine therapy.

Authors:  K Dane Wittrup; Howard L Kaufman; Michael M Schmidt; Darrell J Irvine
Journal:  Expert Opin Drug Deliv       Date:  2022-06-02       Impact factor: 8.129

2.  Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial.

Authors:  Mario Ghosn; Waseem Cheema; Amy Zhu; Jennifer Livschitz; Majid Maybody; Franz E Boas; Ernesto Santos; DaeHee Kim; Jason A Beattie; Michael Offin; Valerie W Rusch; Marjorie G Zauderer; Prasad S Adusumilli; Stephen B Solomon
Journal:  Lung Cancer       Date:  2022-01-06       Impact factor: 6.081

3.  Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy.

Authors:  Maite Alvarez; Carmen Molina; Carlos E De Andrea; Myriam Fernandez-Sendin; Maria Villalba; Jose Gonzalez-Gomariz; Maria Carmen Ochoa; Alvaro Teijeira; Javier Glez-Vaz; Fernando Aranda; Miguel F Sanmamed; Maria E Rodriguez-Ruiz; Xinyi Fan; Wen H Shen; Pedro Berraondo; Marisol Quintero; Ignacio Melero
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

4.  Study on the Correlation Factors of Tumour Prognosis after Intravascular Interventional Therapy.

Authors:  Lei Zheng; Hua Feng; Limin Yin; Jun Wang; Wei Zhou; Sunin Tang; Mingming Li
Journal:  J Healthc Eng       Date:  2021-10-27       Impact factor: 2.682

Review 5.  Techniques for Profiling the Cellular Immune Response and Their Implications for Interventional Oncology.

Authors:  Tushar Garg; Clifford R Weiss; Rahul A Sheth
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.